Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bharat Jasani

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Animals : an Open Access Journal From MDPI|October 14, 2022
The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-OncologySandra Schöniger, Bharat Jasani
American Journal of Clinical Pathology|April 22, 2005
Cell line standards to reduce HER-2/neu assay variation and the potential of automated image analysis to provide more accurate cut points for predicting clinical response to trastuzumabBharat Jasani, Keith Miller
Archives of Pathology & Laboratory Medicine|March 1, 2012
Mesothelioma not associated with asbestos exposureBharat Jasani, Allen Gibbs
Endocrine Pathology|March 7, 2020
Thyroid multifocal granulomatous folliculitis (palpation thyroiditis): An immunocytochemical studyH Ruben Harach, Bharat Jasani
Leukemia Research|April 23, 2013
Can SV40 infect and immortalize human B-lymphocytes and mesothelial cells as a natural pathogen?Bharat Jasani, Janet S Butel
BMJ (Clinical Research Ed.)|February 2, 2002
Variation in rates of oestrogen receptor positivity in breast cancer againKeith Miller, Anthony Rhodes, Bharat Jasani
Biomarkers in Cancer|November 2, 2013
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?Walter P Carney, Dirk Bernhardt, Bharat Jasani
Histopathology|December 3, 2010
Potential unreliability of normal tissue as positive control in diagnostic immunohistochemistry of poorly differentiated carcinomaAnurag Joshi, Murali Varma, Sue Wozniak, et al.
Der Pathologe|October 1, 2020
[ISH-based HER2 diagnostics]Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Der Pathologe|December 21, 2020
ISH-based HER2 diagnosticsJosef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Animals : an Open Access Journal From MDPI|October 14, 2022
The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-OncologySandra Schöniger, Bharat Jasani
American Journal of Clinical Pathology|April 22, 2005
Cell line standards to reduce HER-2/neu assay variation and the potential of automated image analysis to provide more accurate cut points for predicting clinical response to trastuzumabBharat Jasani, Keith Miller
Archives of Pathology & Laboratory Medicine|March 1, 2012
Mesothelioma not associated with asbestos exposureBharat Jasani, Allen Gibbs
Endocrine Pathology|March 7, 2020
Thyroid multifocal granulomatous folliculitis (palpation thyroiditis): An immunocytochemical studyH Ruben Harach, Bharat Jasani
Leukemia Research|April 23, 2013
Can SV40 infect and immortalize human B-lymphocytes and mesothelial cells as a natural pathogen?Bharat Jasani, Janet S Butel
BMJ (Clinical Research Ed.)|February 2, 2002
Variation in rates of oestrogen receptor positivity in breast cancer againKeith Miller, Anthony Rhodes, Bharat Jasani
Biomarkers in Cancer|November 2, 2013
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?Walter P Carney, Dirk Bernhardt, Bharat Jasani
Histopathology|December 3, 2010
Potential unreliability of normal tissue as positive control in diagnostic immunohistochemistry of poorly differentiated carcinomaAnurag Joshi, Murali Varma, Sue Wozniak, et al.
Der Pathologe|October 1, 2020
[ISH-based HER2 diagnostics]Josef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Der Pathologe|December 21, 2020
ISH-based HER2 diagnosticsJosef Rüschoff, Iris Nagelmeier, Bharat Jasani, et al.
Pageof 7